Greg A. Durm

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

The role of maintenance systemic therapy in the treatment of patients with advanced non–small-cell lung cancer (NSCLC) has been a subject of debate for decades. Before the discovery of checkpoint inhibitors (CPIs), the role of maintenance chemotherapy was extensively studied with very modest improvements in survival at the cost of increased toxicity.

Original Article Greg A. Durm MD Corresponding Author E-mail address: gdurm@iu.edu https://orcid.org/0000-0003-2606-745X Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana Corresponding Author: Greg A. Durm, MD, Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Dr, RT 445, Indianapolis, IN 46202 (E-mail address: gdurm@iu.edu).